ArticleJournal of translational medicine2025
TumorXDB: an integrated multi-omics xWAS/xQTL platform for cross-ethnic pan-cancer analysis.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundTumorXDB is a comprehensively curated tumor database integrating molecular association data (xWAS/xQTL) to explore genetic mechanisms across diverse tumors, organs, and ethnic groups. We aimed to provide a unified resource for discovering novel genetic associations and molecular mechanisms in tumors.
methodsTumorXDB integrates four molecular-wide association studies (xWAS) and 23 molecular quantitative trait locus (xQTL) types spanning 10 physiological systems, 50 organs, and 139 cancer subtypes, while incorporating data from 25 ethnic subgroups across four major ancestral populations. To ensure data harmonization, we performed batch-effect correction using ComBat and applied the Benjamini-Hochberg (BH) procedure with false discovery rate (FDR) of < 0.05 for multiple testing correction. Meta-analysis models were developed to generate unified pan-cancer datasets, which are all accessible through a user-friendly web interface ( http://www.tumor-xdb.com ) with full data download capabilities.
resultsTumorXDB enabled robust integration of molecular data, revealing novel cross-cancer genetic associations through harmonized analysis.
conclusionsThis resource advances precision oncology by providing batch-corrected and statistically rigorous pan-cancer data for therapeutic discovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.